Responses
Other responses
Jump to comment:
- Published on: 29 April 2016
- Published on: 29 April 2016
- Published on: 29 April 2016Resveratrol, COPD and Clinical EvaluationShow More
Dear Editor
We thank Andreas von Glehn for his interest in our paper, sufficient that he took resveratrol capsules for his own condition, presumably COPD.[1]
His short course of treatment (9 weeks) highlights the difficulties in evaluating therapies for the treatment of COPD. COPD is a slowly progressive inflammatory condition of the lungs and, as such, clinical trials using lung function measurements a...
Conflict of Interest:
None declared. - Published on: 29 April 2016Resveratrol/COPDShow More
Dear Editor
Regarding the article by Culpitt et al.[1] I wish to comment on the use of Resveratrol and the claims made with regard to COPD. I would interested in learning what evidence the authors have for the claims made. I have, after reading the report and as a patient, tested Resveratrol for 9 weeks without absolutely any result! There were no indications of influence on the immune system or inflammato...
Conflict of Interest:
None declared.